Introduction {#s1}
============

Recent studies have shown that patients with nontuberculous mycobacterial (NTM) infection associated with lung disease are at an increased hospitalization risk [@pone.0099260-Billinger1]--[@pone.0099260-Ringshausen2]. NTM disease such as mycobacterium avium complex (MAC) related lung disease presents not only in immunocompromised patients with acquired immunodeficiency syndrome (AIDS) [@pone.0099260-Wallace1] but also in human immunodeficiency virus (HIV) negative subjects with no underlying disease [@pone.0099260-Huang2]. Studies have also demonstrated that the specific radiographic feature may progress over time, which can be confirmed in histopathologic findings of NTM infection [@pone.0099260-Kim1]. These findings suggest the presence of true infection involving lung tissue invasion in patients with pulmonary NTM disease, rather than colonization even in immunocompetent patients [@pone.0099260-Jeong1]. Meanwhile, Moore et al. suggested that the bronchiectasis in NTM patients with lung lesions is not a preexisting condition but a result from NTM infection [@pone.0099260-Moore1].

Respiratory failure (RF) occurs as the exchange between O~2~ and CO~2~ fails to meet the need of metabolism, leading to hypoxaemia, with or without hypercarbia. The diagnosis of RF requires to measure arterial blood gases, including the partial pressure of O~2~ (P~a~O~2~) and the partial pressure of CO~2~ (P~a~CO~2~) in the arterial blood. RF can be defined as P~a~O~2~\<8 kPa (60 mmHg), or P~a~CO~2~\>6.7 kPa (50 mHg) for a patient at rest, breathing air at sea level [@pone.0099260-Sue1]--[@pone.0099260-Behrendt1]. Acute respiratory failure (ARF) develops over several minutes to hours, because of absence of oxygen delivery to the blood or because of an acute failure to remove carbon dioxide (CO~2~) from the blood by the respiratory system. Chronic respiratory failure (CRF) develops over several days or longer [@pone.0099260-Sue1], [@pone.0099260-Roussos1]. ARF on CRF is owing to acute exacerbation of CRF [@pone.0099260-Sue1], [@pone.0099260-Roussos1].

RF is a major cause leading to intensive-care for patients requiring hospitalization and mechanical ventilation [@pone.0099260-Shu1]. The etiology of RF has been associated with tuberculosis, pneumonia, bronchopneumonia, diabetes, chronic obstructive pulmonary disease (COPD), pneumococcosis, end-stage renal disease(ESRD), malnutrition and AIDS [@pone.0099260-Behrendt1], [@pone.0099260-Gong1]--[@pone.0099260-Orsini1]. Several studies also reported that these factors are predisposing factors of NTM infection [@pone.0099260-Billinger1]--[@pone.0099260-Shu1], [@pone.0099260-Erasmus1]--[@pone.0099260-Andrejak1]. The NTM infection has been associated with the risk of not only ARF [@pone.0099260-Billinger1], [@pone.0099260-Ringshausen1] but also CRF [@pone.0099260-Andrejak1] in hospitalized patients. No detailed study has addressed the RF risk for inpatients with NTM infection. This retrospective cohort study was designed to use a large population data to evaluate the risk of RF for patients with NTM infection, comparing with the general population [@pone.0099260-Booth1], [@pone.0099260-Booth2]. Therefore, we measured the incidence of RF between subjects with and without NTM infection by demographic status and comorbidity using the health insurance claims data of Taiwan.

Materials and Methods {#s2}
=====================

Data Source {#s2a}
-----------

The National Health Insurance (NHI) program of Taiwan is a universal insurance program established in 1995, reforming from 13 insurance-related systems, and providing health care to 99% of approximately 23 million people in Taiwan. We used the National Health Insurance Research Database (NHIRD) obtained from the insurance system to identify patients and health care providers. The data sets consisted of claim data for outpatients, inpatients, catastrophic illnesses registry and registry of beneficiaries for the period from 1996 to 2010. Patients demographic status including sex, birth date, medical services and medications, and costs were available in these data files. All personal identification numbers had been encrypted before releasing to the public to protect patient privacy. We identified diseases using codes of the International Classification of Diseases, 9^th^ Revision, Clinical Modification (ICD-9-CM) [@pone.0099260-Carol1]. An ad hoc committee was available in the Bureau of Insurance to monitor the claims. Institutions with violation receive penalty.

Ethics Statement {#s2b}
----------------

Because identification numbers of patients had been encrypted, patient consent was not required for this study. This study was approved by the Research Ethic Committee at China Medical University (CMU-REC-101-012). The committee waived the requirement for consent.

Study Population {#s2c}
----------------

This population-based retrospective cohort study identified a cohort of NTM patients (ICD-9-CM 031.0, 031.2, 031.8, 0.31.9) newly diagnosed from 1999 to 2009 from inpatient claims data. We further randomly selected 15456 individuals free of NTM infection in the reimbursement claim data files as the comparison cohort or non-NTM cohort, frequency-matched by sex, age and index year. The principal outcome was RF (ICD-9-CM 518.81, 518.83, 518.84). Subjects who had experienced RF prior to the baseline year were excluded in both cohorts. Follow-up was terminated by the identification of a RF event or at the end of 2010 or censored for death and loss to follow-up.

Comorbidities with potential association with RF were identified at the baseline [@pone.0099260-Billinger1]--[@pone.0099260-Kim1], [@pone.0099260-Behrendt1]--[@pone.0099260-Andrejak1], including tuberculoses (ICD-9-CM 010--018), bronchopneumonia (ICD-9-CM 485), pneumonia (ICD-9-CM 486), diabetes (ICD-9-CM 250), chronic obstructive pulmonary disease (COPD; ICD-9-CM 490--492), liver cirrhosis, (ICD-9-CM 571), end stage renal disease (ESRD; ICD-9-CM 585), human immunodeficiency virus (HIV; ICD-9-CM 042--044, 795.8, V08), pneumoconiosis and other lung diseases due to external agents (ICD-9-CM 500--508) and malnutrition (ICD-9-CM 260--269), identified from inpatient claim data, and cancer (ICD-9-CM 140--208) identified from the catastrophic illness registry. Patients with NTM were further divided into the MAC (ICD-9-CM 031.0, 031.2) and non-MAC (ICD-9-CM 031.8, 0.31.9) subgroups.

Statistical Analysis {#s2d}
--------------------

Data analyses used the Chi-square test to examine categorical variables and Student's *t*-test to assess continuous variables between NTM and non-NTM cohorts for the baseline data. The RF incidence rate was calculated for each cohort. The cumulative proportional incidences of RF were measured using the Kaplan-Meier method for both cohorts during the follow-up period, and examined with the log-rank test. Cox proportional hazards regression was applied to estimate the hazard ratio (HR) and 95% confidence interval (CI) of RF for the NTM cohort, compared with the non-NTM cohort. Data analysis further differentiate the risk between NTM patients with MAC and without (non-MAC).

All statistical analyses were performed using the SAS 9.3 statistical package (SAS Institute Inc., NC, USA). R software (R Foundation for Statistical Computing, Vienna, Austria) was used to construct the Kaplan-Meier curves. A *p-value\<*0.05 in 2-tailed tests was considered significant.

Results {#s3}
=======

The study population consisted of 3,864 NTM patients and 15,456 non-NTM comparisons, with similar distributions in sex, age (mean 55.7 year) and occupation ([Table 1](#pone-0099260-t001){ref-type="table"}). The NTM cohort had lower income and were more likely have pre-existing comorbidities than the comparison cohort (*P*\<0.001). Kaplan-Meier model estimated cumulative incidence of RF was 10% higher in the NTM cohort than the non-NTM cohort ([Figure 1](#pone-0099260-g001){ref-type="fig"}; *P*\<0.0001 in the log rank test).

![Cumulative incidence of respiratory failure among patients with non-TB mycobacterial infection (dashed line) and among compared subjects.](pone.0099260.g001){#pone-0099260-g001}

10.1371/journal.pone.0099260.t001

###### Comparison of demographics and comorbidities between non-TB mycobacterial infection cohort and comparison cohort.

![](pone.0099260.t001){#pone-0099260-t001-1}

                                                 Non-TB mycobacterial infection                                 
  --------------------------------------------- -------------------------------- --------------- ------ ------- ---------
  Sex[†](#nt101){ref-type="table-fn"}                                                                             0.98
  Women                                                       5816                    37.63       1454   37.63  
  Men                                                         9640                    62.37       2410   62.37  
  Age, year[†](#nt101){ref-type="table-fn"}                                                                       0.98
  \<65                                                        9388                    60.74       2347   60.74  
  ≥65                                                         6068                    39.26       1517   39.26  
  Mean (SD)[\#](#nt102){ref-type="table-fn"}             55.70 (21.10)            55.73 (21.10)   0.93          
  Income, NTD[†](#nt101){ref-type="table-fn"}                                                                    \<.0001
  \<15000                                                     7456                    48.24       2017   52.20  
  15000--25000                                                5057                    32.72       1264   32.71  
  ≥25000                                                      2943                    19.04       583    15.09  
  Occupation[†](#nt101){ref-type="table-fn"}                                                                      0.31
  White collar                                                7467                    48.31       1801   46.61  
  Blue collar                                                 5890                    38.11       1523   39.42  
  Others                                                      2047                    13.24       527    13.64  
  Comorbidity[†](#nt101){ref-type="table-fn"}                                                                   
  Tuberculosis                                                169                     1.09        900    23.29   \<.0001
  Bronchopneumonia                                            128                     0.83        154    3.99    \<.0001
  Pneumonia                                                   511                     3.31        795    20.57   \<.0001
  COPD                                                        583                     3.77        766    19.82   \<.0001
  Pneumoconiosis                                               70                     0.45        101    2.61    \<.0001
  Diabetes                                                    2505                    16.21       748    19.36   \<.0001
  Liver cirrhosis                                             505                     3.27        316    8.18    \<.0001
  Cancer                                                      495                     3.20        363    9.39    \<.0001
  ESRD                                                         67                     0.43         76    1.97    \<.0001
  Malnutrition                                                 37                     0.24         59    1.53    \<.0001
  HIV                                                          3                      0.02        186    4.81    \<.0001

Chi-square test;

Student's t-test.

[Table 2](#pone-0099260-t002){ref-type="table"} shows that the incidence of RF in the NTM cohort was 4.31-fold higher than that in the comparison cohort (44.0 vs. 10.2 per 1000 person-years), with an adjusted HR of 3.11 (95% CI: 2.73--3.54) (*p*\<0.001). The RF incidence was higher in men, the elderly, low income people and subjects with blue collar jobs. Comorbidity increased the risk of RF in both cohorts, particularly in NTM patients with COPD with an incidence of 144.5 per 1000 person-years, which was 5.1-fold greater than the incidence in NTM patients without COPD.

10.1371/journal.pone.0099260.t002

###### Incidence of respiratory failure by sex, age, income, occupation and comorbidity and adjusted hazard ratio for patients with non-TB mycobacterial infection compared with comparison subjects without non-TB mycobacterial infection.

![](pone.0099260.t002){#pone-0099260-t002-2}

                    Non-TB mycobacterial infection   Compared to comparisons                                                    
  ---------------- -------------------------------- ------------------------- ------- ----- ------- -------- ------------------ ------------------
  All                            675                          66162            10.20   587   13337   44.01    4.31(4.00--4.65)   3.11(2.73--3.54)
  Sex                                                                                                                           
  Women                          206                          24811            8.30    164   5298    30.95    3.73(3.28--4.24)   2.67(2.11--3.39)
  Men                            469                          41351            11.34   423   8038    52.62    4.64(4.22--5.10)   3.32(2.84--3.87)
  Age, year                                                                                                                     
  \<65                            87                          43720            1.99    174   9569    18.18    9.14(8.15--10.2)   4.42(3.28--5.96)
  ≥65                            588                          22442            26.20   413   3767    109.63   4.18(3.76--4.66)   2.52(2.17--2.92)
  Income, NTD^†^                                                                                                                
  \<15000                        459                          31229            14.7    375   6477    57.89    3.94(3.55--4.37)   2.88(2.45--3.39)
  15000--25000                   198                          21332            9.28    181   4468    40.51    4.36(3.81--4.99)   3.38(2.68--4.27)
  ≥25000                          18                          13601            1.32    31    2391    12.97    9.80(7.86--12.2)   6.36(3.33--12.1)
  Occupation                                                                                                                    
  White collar                   219                          32666            6.70    225   6478    34.73    5.18(4.62--5.81)   3.47(2.79--4.33)
  Blue collar                    298                          25077            11.88   247   5243    47.11    3.96(3.51--4.47)   2.99(2.45--3.64)
  Others                         158                          8287             19.07   115   1591    72.30    3.79(3.12--4.61)   2.93(2.19--3.91)
  Comorbidity                                                                                                                   
  No                             274                          52656            5.20    93    7007    13.27    2.55(2.27--2.86)   3.50(2.76--4.43)
  Yes                            401                          13505            29.69   494   6330    78.04    2.63(2.33--2.97)   3.67(3.21--4.20)
  COPD                                                                                                                          
  No                             549                          64434            8.52    326   11530   28.27    3.32(3.05--3.61)   3.27(2.81--3.81)
  Yes                            126                          1728             72.93   261   1806    144.51   1.98(1.56--2.51)   2.31(1.81--2.94)
  Diabetes                                                                                                                      
  No                             440                          57077            7.71    416   11181   37.20    4.83(4.43--5.26)   3.50(2.99--4.09)
  Yes                            235                          9085             25.87   171   2155    79.35    3.07(2.59--3.63)   2.33(1.85--2.93)

PY, person-years; Rate^\#^, incidence rate, per 1,000 person-years; IRR^\*^, incidence rate ratio; CI, confidence interval; Adjusted HR^†^: multivariable analysis included age, sex, income, occupation, and comorbidities.; all p\<0.001.

[Table 3](#pone-0099260-t003){ref-type="table"} shows the trends of RF events by follow-up in both cohorts. The incidence of RF decreased with follow-up time in both cohorts, higher in the NTM cohort than in the non-NTM cohort. The NTM cohort had an adjusted HR of 7.45 (95% CI: 5.50--10.1) (*p*\<0.001) in the first 6 months of follow-up.

10.1371/journal.pone.0099260.t003

###### Incidence of respiratory failure events in study cohorts by follow-up time and hazard ratio for patients with non-TB mycobacterial infection.

![](pone.0099260.t003){#pone-0099260-t003-3}

                  Without non-TB mycobacterial infection   With non-TB mycobacterial infection                                                   
  -------------- ---------------------------------------- ------------------------------------- ------- ----- ------ -------- ------------------ ------------------
  \<6 months                        73                                    7667                   9.52    186   1794   103.69   10.9(9.90--12.0)   7.45(5.50--10.1)
  6--12 months                      89                                    7538                   11.81   98    1626   60.25    5.10(4.65--5.61)   3.47(2.47--4.86)
  1--3 years                       263                                    24208                  10.86   186   4873   38.17    3.51(3.22--3.84)   2.49(1.99--3.11)
  3--5 years                       141                                    14461                  9.75    60    2774   21.63    2.22(1.95--2.52)   1.50(1.04--2.16)
  ≥5 years                         109                                    12288                  8.87    57    2269   25.12    2.83(2.44--3.29)   2.85(2.01--4.04)

PY, person-years; Rate^\#^, incidence rate, per 1,000 person-years; IRR^\*^, incidence rate ratio; CI, confidence interval; Adjusted HR^†^: multivariable analysis included age, sex, income, occupation, and comorbidities.; p\<0.001.

Data analysis further stratified the NTM cohort into MAC and non-MAC subgroups. The incidence of RF was 2.6-fold greater for those with MAC than those without MAC in the NTM cohort ([Table 4](#pone-0099260-t004){ref-type="table"}).

10.1371/journal.pone.0099260.t004

###### Incidence and adjusted hazard ratio of respiratory failure associated with mycobacterium avium complex in patients with non-TB mycobacterial infection.

![](pone.0099260.t004){#pone-0099260-t004-4}

  Variables                              Event         PY    Rate^\#^   IRR^\*^(95% CI)   Adjusted HR^†^(95% CI)  
  ------------------------------- ------------------- ----- ---------- ----------------- ------------------------ ------------------
  Non-TBmycobacterial infection    Comparison cohort   675    66162          10.2                  1.00                  1.00
                                          MAC          307     3947          77.8            7.62(6.95--8.36)      3.51(2.98--4.12)
                                        Non-MAC        280     9390          29.8            2.92(2.66--3.21)      2.85(2.46--3.31)

PY, person-years; Rate^\#^, incidence rate, per 1,000 person-years; IRR^\*^, incidence rate ratio; CI, confidence interval; Adjusted HR^†^: multiple analysis including age, sex, income and comorbidities; NTM, non-TB mycobacterial infection; MAC, mycobacterium avium complex; Non-MAC, none mycobacterium avium complex; p\<0.001.

Discussion {#s4}
==========

In the present study, NTM patients exhibited a 4.3-fold higher incidence of RF than the general population, with a HR of 3.11 after adjusting for age, sex, income, occupation, and comorbidities ([Table 2](#pone-0099260-t002){ref-type="table"}). The RF risk increased with age and higher in men than in women. However, the relative HR was higher in younger NTM patients than in the elderly patients (HR: 4.42 vs. 2.52) and higher in men than in women (HR 3.32 vs. 2.67). Lee et al. found a substantial decline in lung function in young NTM patients. [@pone.0099260-Lee1]. Their findings are consistent with our findings. Therefore, attention should be given to patients with these risk factors.

Comorbidities were more prevalent in the NTM cohort than in the non-NTM cohort in this study. These comorbidities are also risk factors of NTM disease and RF. Among comorbidities, only COPD and diabetes have significant joint effect with NTM for developing RF (see Table S1 in [File S1](#pone.0099260.s001){ref-type="supplementary-material"}). Huang et al. have found that patients with *M. abscessus* infection without MAC in subtropical chronic ventilatory setting are at a high risk of RF and 39.3% (n = 11) patients with diabetes [@pone.0099260-Huang1]. On the other hand, Shu et al. have reported that NTM patients are admitted to an intensive care unit mainly with RF (81%), less often with COPD exacerbation (1%), and diabetes was not associated with RF [@pone.0099260-Shu1]. NTM pulmonary infection may cause an underlying comorbid conditions leading to RF [@pone.0099260-Shu1], [@pone.0099260-Kim1]--[@pone.0099260-Moore1], which in turn worsens the pulmonary function [@pone.0099260-Shu1], [@pone.0099260-Miravitlles1]. Meanwhile, the MAC infection can lead to air trapping distal to the small airways for NTM patients [@pone.0099260-Kubo1]. Several studies have found that NTM patients with worse pulmonary test [@pone.0099260-Lee1], [@pone.0099260-Lee2] has a higher risk of RF because of comorbidities [@pone.0099260-Billinger1], [@pone.0099260-Ringshausen1], [@pone.0099260-Ringshausen2], [@pone.0099260-Koh1]--[@pone.0099260-Systrom1]. In our study, the multivariate analysis showed that NTM patients with MAC have a much higher incidence of RF than those without MAC. COPD and diabetes further increase the risk of RF.

This study showed that patients diagnosed with NTM within 6 months had the highest risk of RF with an adjusted HR of 7.45 and the HR decreased with follow-up. Shu et al. have reported that the 6-month survival in NTM patients with lung lesion is poor based on a single hospital study. The survival is particularly poor for those with worsening consolidation and cavitation of lung [@pone.0099260-Shu2]. An earlier study found that 72% of patients with lung consolidation suffered from ARF [@pone.0099260-Shu1]. Lung destruction appears soon after NTM is diagnosed and the lung function impairment follows [@pone.0099260-Shu1], [@pone.0099260-Shu2].

Studies also found that bronchiectasis carries a worse prognosis [@pone.0099260-Shu2] and develops RF with a relatively slow and indolent course among NTM patients [@pone.0099260-Ringshausen2], [@pone.0099260-Andrejak1], [@pone.0099260-Koh1]. COPD has a strong association with bronchiectasis in previous study [@pone.0099260-Ringshausen2]. Meanwhile, NTM is a potential risk factor for COPD [@pone.0099260-Yeh1]. Furthermore, COPD is an important cause of RF [@pone.0099260-Sue1], [@pone.0099260-Roussos1]. These findings highlight the importance of identifying NTM patients who are likely to have RF.

Studies have found patients with NTM are at a higher risk of fast decline of pulmonary function [@pone.0099260-Shu2], and the decline of lung function is even greater than patients with COPD [@pone.0099260-Lee1]. In addition, Ringshausen et al. found 20.4% of patients with the NTM lung disease develop RF [@pone.0099260-Ringshausen1]. These studies confirm our findings. The cumulative proportional incidence of RF is higher among patients with NTM infection than those without the infection. We have performed additional data analysis to estimated the RF incidence for the 2 study cohorts by the follow-up time of \<1 year and ≥1 year with the adjusted HRs of 5.31 (95% CI: 4.26--6.63) and 2.33 (95% CI: 1.97--2.75), respectively, (p\<0.0001, Table S2 in [File S1](#pone.0099260.s001){ref-type="supplementary-material"}). Patients with delayed diagnosis of NTM could develop RF episode and require ICU intervention sooner.

Recent studies have reported the delayed diagnosis of Mycobacterium kansasii septicemia [@pone.0099260-Shaaban1], drug resistance [@pone.0099260-Babalik1], and outbreak of nosocomial NTM infection [@pone.0099260-Kazumi1] may also contribute to the development of RF in patients with NTM infections. Most NTM patients develop granulomatous inflammation and a large portion have a cavity difficult to distinguish from tuberculosis in the clinical and radiological findings [@pone.0099260-Griffith1]. In countries with a high prevalence of tuberculosis, NTM is likely misdiagnosed as tuberculosis. Thus there is a critical need to improve the diagnostic capacity of mycobacterial disease to highlight the awareness of NTM disease prevalence [@pone.0099260-Shaaban1].

A Japanese study found subjects with NTM pulmonary infection but normal underlying lung anatomy developing bronchiectasis because of bronchial wall infection and necrosis similar to tuberculosis [@pone.0099260-Zheng1]. Su et al. have reported that 24 out of 43 patients (56%) with NTM disease without comorbidities were admitted to ICU because of RF [@pone.0099260-Shu1]. The risk of the RF in the NTM cohort without comorbidities were higher than in the cohort without NTM (HR 3.50, 95% CI, 2.76--4.43) in the present study may support this finding. In the Kubo et al. study, patients with pulmonary MAC infection with no evidence of predisposing lung disease could lead to air trapping distal to the small airways [@pone.0099260-Kubo1] and bronchiectasis [@pone.0099260-Moore1]. Meanwhile, Yamazaki et al. suggested that small airway dysfunction in MAC Infection without predisposing lung disease relating to the inflammation is probably related to the neutrophil [@pone.0099260-Yamazaki1]. These findings imply the NTM infection without comorbid disease is still critical to the development of RF [@pone.0099260-Prince1].

The strength of this study is using a nationwide population data to perform the longitudinal assessment of RF risk in patients with NTM disease. These findings can be generalized to the general population. However, limitations must be considered when interpreting these findings. The insurance claims data provided no detailed information on smoking, body mass index, chest wall deformities, and environmental exposures. We were unable to assess how these factors are associated with the development of RF for patients with NTM in this study. However, we have performed an additional data analysis with a much smaller sample size for the non-NTM cohort (N = 3864), frequency matched by socio-demographic factors and comorbidities, including COPD as well (Table S3 in [File S1](#pone.0099260.s001){ref-type="supplementary-material"}). The results showed that the incidence of RF was 2.08-fold higher in the NTM cohort than in the non-NTM cohort with a HR of 2.27 (95% CI: 1.98--2.60) (Table S4 in [File S1](#pone.0099260.s001){ref-type="supplementary-material"}), indicating the impact of NTM remains strong. It is possible that disease diagnoses may be mistakenly coded in the claims data. To avoid misclassification, only patients with two diagnoses in 12 months were considered in this study. Meanwhile, the major types of infections caused by NTM included isolated pulmonary infection and pleurisy (59.5%) [@pone.0099260-Ding1]. Study also found that few NTM patients with culture-positive specimens are clinical significant for RF in practice [@pone.0099260-Simons1]. Patients with NTM infection without medical care could be excluded from the NTM cohort and under estimated the hazards in this study. These finding may need further intervention in future.

Conclusion {#s5}
==========

In this nationwide study, we followed a large number of inpatients with nontuberculous mycobacterial infection with a mean follow-up of 4 years. These patients have a HR of 3.11 to develop respiratory failure compared with the general population. The risk is much greater in the first 6 months post diagnosis. The incidence of respiratory failure increases further for patients with other comorbidities particularly for those with chronic obstructive pulmonary disease and diabetes. Patients with mycobacterium avium complex are also at much higher risk of respiratory failure. These findings suggest that an early diagnosis of nontuberculous mycobacterial disease may assist in preventing respiratory failure.
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